Company / SG&A Expense
Zimmer Biomet SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$3.3B
FY2025
5-year range
$2.8B / $3.3B
FY2021-FY2025
Trend
+11.2%
vs FY2024
Sector context
#18 of 158
Health Care
What the data says
Zimmer Biomet's sg&a expense of $3.3B is higher than 89% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 3 consecutive years, from $2.8B in FY2022 to $3.3B in FY2025.
Based on SEC 10-K filings.
$3.3B in FY2025 with a 5-year CAGR of +3.7%. Top quartile in the Health Care sector.
Increased from $2.8B to $3.3B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +5.7%
- 5-Year CAGR
- +3.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 158This company $3.3B Sector average $175.9B
▼
-98.1% below sector average
Key checks
Key Insights
- Zimmer Biomet's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +3.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 11.2% year-over-year.
- Ranks #18 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.3B | +11.2% |
| FY2024 | $2.9B | +3.2% |
| FY2023 | $2.8B | +2.8% |
| FY2022 | $2.8B | -2.9% |
| FY2021 | $2.8B | +4.8% |
| FY2020 | $2.7B | -12.6% |
| FY2019 | $3.1B | +5.4% |
| FY2018 | $2.9B | -5.2% |
| FY2017 | $3.1B | +77.3% |
| FY2016 | $1.8B | -23.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026